| . | BMM reporting completion . | . | Total . |
|---|---|---|---|
| . | No . | Yes . | . |
| . | n (%) . | n (%) . | . |
| Total | 1573 (18.9) | 6733 (81.1) | 8306 |
| Age at diagnosis, years (yrs) | |||
| 40–44 | 55 (14.8) | 317 (85.2) | 372 |
| 45–49 | 104 (18.4) | 460 (81.6) | 564 |
| 50–54 | 126 (17.5) | 594 (82.5) | 720 |
| 55–59 | 187 (17.0) | 910 (83.0) | 1097 |
| 60–64 | 240 (18.1) | 1086 (81.9) | 1326 |
| 65–69 | 282 (19.8) | 1140 (80.2) | 1422 |
| 70+ | 579 (20.6) | 2226 (79.4) | 2805 |
| Sex | |||
| Male | 911 (18.7) | 3958 (81.3) | 4869 |
| Female | 662 (19.3) | 2775 (80.7) | 3437 |
| Race/Ethnicity | |||
| White, non-Hispanic | 1246 (18.4) | 5529 (81.6) | 6775 |
| Black, non-Hispanic | 94 (20.0) | 375 (80.0) | 469 |
| Hispanic | 128 (23.0) | 429 (77.0) | 557 |
| Asian/Pacific Islander | 45 (19.7) | 183 (80.3) | 228 |
| Other | 60 (21.7) | 217 (78.3) | 277 |
| Prior cancer diagnosis | |||
| No | 1332 (18.8) | 5742 (81.2) | 7074 |
| Yes | 241 (19.6) | 991 (80.4) | 1232 |
| Histopathological type | |||
| Glioblastoma (9440/3) | 1373 (19.8) | 5556 (80.2) | 6929 |
| Astrocytoma (9400/3 or 9401/3) | 173 (17.6) | 810 (82.4) | 983 |
| Oligodendroglioma (9450/3 or 9451/3) | 27 (6.9) | 367 (93.1) | 394 |
| Primary site | |||
| Brain, NOS | 166 (23.4) | 543 (76.6) | 709 |
| Infratentorial | 18 (22.0) | 64 (78.0) | 82 |
| Overlapping lesion | 185 (17.8) | 856 (82.2) | 1041 |
| Supratentorial | 1204 (18.6) | 5270 (81.4) | 6474 |
| WHO grade | |||
| 2 | 57 (10.9) | 466 (89.1) | 523 |
| 3 | 120 (15.5) | 652 (84.5) | 772 |
| 4 | 1396 (19.9) | 5615 (80.1) | 7011 |
| Insurance status | |||
| Private | 608 (18.1) | 2755 (81.9) | 3363 |
| Medicaid | 106 (17.3) | 505 (82.7) | 611 |
| Medicare | 782 (19.9) | 3141 (80.1) | 3923 |
| Other governmental | 24 (13.2) | 158 (86.8) | 182 |
| Uninsured | 53 (23.3) | 174 (76.7) | 227 |
| ZIP code-level household income (quartiles) | |||
| Q1 | 256 (21.7) | 923 (78.3) | 1179 |
| Q2 | 323 (19.7) | 1314 (80.3) | 1637 |
| Q3 | 371 (19.2) | 1564 (80.8) | 1935 |
| Q4 | 623 (17.5) | 2932 (82.5) | 3555 |
| Extent of resection | |||
| Biopsy-only | 624 (23.6) | 2024 (76.4) | 2648 |
| Subtotal resection | 503 (16.3) | 2592 (83.7) | 2563 |
| Gross total resection | 446 (17.4) | 2117 (82.6) | 3095 |
| Facility cancer program type | |||
| Academic/research | 575 (14.6) | 3364 (85.4) | 3939 |
| Community | 87 (32.7) | 179 (67.3) | 266 |
| Comprehensive community | 624 (24.9) | 1878 (75.1) | 2502 |
| Integrated network | 287 (17.9) | 1312 (82.1) | 1599 |
| Diagnosing hospital | |||
| Elsewhere | 413 (16.4) | 2105 (83.6) | 2518 |
| Reporting facility | 1160 (20.0) | 4628 (80.0) | 5788 |
| Facility location | |||
| New England | 73 (13.2) | 479 (86.8) | 552 |
| East North Central | 249 (18.7) | 1082 (81.3) | 1331 |
| East South Central | 130 (24.4) | 402 (75.6) | 532 |
| Middle Atlantic | 259 (20.3) | 1015 (79.7) | 1274 |
| Mountain | 64 (17.8) | 296 (82.2) | 360 |
| Pacific | 196 (17.2) | 944 (82.8) | 1140 |
| South Atlantic | 346 (19.5) | 1431 (80.5) | 1777 |
| West North Central | 87 (13.7) | 549 (86.3) | 636 |
| West South Central | 169 (24.0) | 535 (76.0) | 704 |
| Urbanicity | |||
| Metro | 1339 (18.9) | 5,732 (81.1) | 7071 |
| Rural | 150 (20.2) | 592 (79.8) | 742 |
| Urban | 84 (17.0) | 409 (83.0) | 493 |
| . | BMM reporting completion . | . | Total . |
|---|---|---|---|
| . | No . | Yes . | . |
| . | n (%) . | n (%) . | . |
| Total | 1573 (18.9) | 6733 (81.1) | 8306 |
| Age at diagnosis, years (yrs) | |||
| 40–44 | 55 (14.8) | 317 (85.2) | 372 |
| 45–49 | 104 (18.4) | 460 (81.6) | 564 |
| 50–54 | 126 (17.5) | 594 (82.5) | 720 |
| 55–59 | 187 (17.0) | 910 (83.0) | 1097 |
| 60–64 | 240 (18.1) | 1086 (81.9) | 1326 |
| 65–69 | 282 (19.8) | 1140 (80.2) | 1422 |
| 70+ | 579 (20.6) | 2226 (79.4) | 2805 |
| Sex | |||
| Male | 911 (18.7) | 3958 (81.3) | 4869 |
| Female | 662 (19.3) | 2775 (80.7) | 3437 |
| Race/Ethnicity | |||
| White, non-Hispanic | 1246 (18.4) | 5529 (81.6) | 6775 |
| Black, non-Hispanic | 94 (20.0) | 375 (80.0) | 469 |
| Hispanic | 128 (23.0) | 429 (77.0) | 557 |
| Asian/Pacific Islander | 45 (19.7) | 183 (80.3) | 228 |
| Other | 60 (21.7) | 217 (78.3) | 277 |
| Prior cancer diagnosis | |||
| No | 1332 (18.8) | 5742 (81.2) | 7074 |
| Yes | 241 (19.6) | 991 (80.4) | 1232 |
| Histopathological type | |||
| Glioblastoma (9440/3) | 1373 (19.8) | 5556 (80.2) | 6929 |
| Astrocytoma (9400/3 or 9401/3) | 173 (17.6) | 810 (82.4) | 983 |
| Oligodendroglioma (9450/3 or 9451/3) | 27 (6.9) | 367 (93.1) | 394 |
| Primary site | |||
| Brain, NOS | 166 (23.4) | 543 (76.6) | 709 |
| Infratentorial | 18 (22.0) | 64 (78.0) | 82 |
| Overlapping lesion | 185 (17.8) | 856 (82.2) | 1041 |
| Supratentorial | 1204 (18.6) | 5270 (81.4) | 6474 |
| WHO grade | |||
| 2 | 57 (10.9) | 466 (89.1) | 523 |
| 3 | 120 (15.5) | 652 (84.5) | 772 |
| 4 | 1396 (19.9) | 5615 (80.1) | 7011 |
| Insurance status | |||
| Private | 608 (18.1) | 2755 (81.9) | 3363 |
| Medicaid | 106 (17.3) | 505 (82.7) | 611 |
| Medicare | 782 (19.9) | 3141 (80.1) | 3923 |
| Other governmental | 24 (13.2) | 158 (86.8) | 182 |
| Uninsured | 53 (23.3) | 174 (76.7) | 227 |
| ZIP code-level household income (quartiles) | |||
| Q1 | 256 (21.7) | 923 (78.3) | 1179 |
| Q2 | 323 (19.7) | 1314 (80.3) | 1637 |
| Q3 | 371 (19.2) | 1564 (80.8) | 1935 |
| Q4 | 623 (17.5) | 2932 (82.5) | 3555 |
| Extent of resection | |||
| Biopsy-only | 624 (23.6) | 2024 (76.4) | 2648 |
| Subtotal resection | 503 (16.3) | 2592 (83.7) | 2563 |
| Gross total resection | 446 (17.4) | 2117 (82.6) | 3095 |
| Facility cancer program type | |||
| Academic/research | 575 (14.6) | 3364 (85.4) | 3939 |
| Community | 87 (32.7) | 179 (67.3) | 266 |
| Comprehensive community | 624 (24.9) | 1878 (75.1) | 2502 |
| Integrated network | 287 (17.9) | 1312 (82.1) | 1599 |
| Diagnosing hospital | |||
| Elsewhere | 413 (16.4) | 2105 (83.6) | 2518 |
| Reporting facility | 1160 (20.0) | 4628 (80.0) | 5788 |
| Facility location | |||
| New England | 73 (13.2) | 479 (86.8) | 552 |
| East North Central | 249 (18.7) | 1082 (81.3) | 1331 |
| East South Central | 130 (24.4) | 402 (75.6) | 532 |
| Middle Atlantic | 259 (20.3) | 1015 (79.7) | 1274 |
| Mountain | 64 (17.8) | 296 (82.2) | 360 |
| Pacific | 196 (17.2) | 944 (82.8) | 1140 |
| South Atlantic | 346 (19.5) | 1431 (80.5) | 1777 |
| West North Central | 87 (13.7) | 549 (86.3) | 636 |
| West South Central | 169 (24.0) | 535 (76.0) | 704 |
| Urbanicity | |||
| Metro | 1339 (18.9) | 5,732 (81.1) | 7071 |
| Rural | 150 (20.2) | 592 (79.8) | 742 |
| Urban | 84 (17.0) | 409 (83.0) | 493 |
Testing/reporting was defined as having a BMM code of 1–9 or 87, while a code of 88 or 99 was defined as no testing and reporting.
Abbreviations: BMM = Brain Molecular Markers.
| . | BMM reporting completion . | . | Total . |
|---|---|---|---|
| . | No . | Yes . | . |
| . | n (%) . | n (%) . | . |
| Total | 1573 (18.9) | 6733 (81.1) | 8306 |
| Age at diagnosis, years (yrs) | |||
| 40–44 | 55 (14.8) | 317 (85.2) | 372 |
| 45–49 | 104 (18.4) | 460 (81.6) | 564 |
| 50–54 | 126 (17.5) | 594 (82.5) | 720 |
| 55–59 | 187 (17.0) | 910 (83.0) | 1097 |
| 60–64 | 240 (18.1) | 1086 (81.9) | 1326 |
| 65–69 | 282 (19.8) | 1140 (80.2) | 1422 |
| 70+ | 579 (20.6) | 2226 (79.4) | 2805 |
| Sex | |||
| Male | 911 (18.7) | 3958 (81.3) | 4869 |
| Female | 662 (19.3) | 2775 (80.7) | 3437 |
| Race/Ethnicity | |||
| White, non-Hispanic | 1246 (18.4) | 5529 (81.6) | 6775 |
| Black, non-Hispanic | 94 (20.0) | 375 (80.0) | 469 |
| Hispanic | 128 (23.0) | 429 (77.0) | 557 |
| Asian/Pacific Islander | 45 (19.7) | 183 (80.3) | 228 |
| Other | 60 (21.7) | 217 (78.3) | 277 |
| Prior cancer diagnosis | |||
| No | 1332 (18.8) | 5742 (81.2) | 7074 |
| Yes | 241 (19.6) | 991 (80.4) | 1232 |
| Histopathological type | |||
| Glioblastoma (9440/3) | 1373 (19.8) | 5556 (80.2) | 6929 |
| Astrocytoma (9400/3 or 9401/3) | 173 (17.6) | 810 (82.4) | 983 |
| Oligodendroglioma (9450/3 or 9451/3) | 27 (6.9) | 367 (93.1) | 394 |
| Primary site | |||
| Brain, NOS | 166 (23.4) | 543 (76.6) | 709 |
| Infratentorial | 18 (22.0) | 64 (78.0) | 82 |
| Overlapping lesion | 185 (17.8) | 856 (82.2) | 1041 |
| Supratentorial | 1204 (18.6) | 5270 (81.4) | 6474 |
| WHO grade | |||
| 2 | 57 (10.9) | 466 (89.1) | 523 |
| 3 | 120 (15.5) | 652 (84.5) | 772 |
| 4 | 1396 (19.9) | 5615 (80.1) | 7011 |
| Insurance status | |||
| Private | 608 (18.1) | 2755 (81.9) | 3363 |
| Medicaid | 106 (17.3) | 505 (82.7) | 611 |
| Medicare | 782 (19.9) | 3141 (80.1) | 3923 |
| Other governmental | 24 (13.2) | 158 (86.8) | 182 |
| Uninsured | 53 (23.3) | 174 (76.7) | 227 |
| ZIP code-level household income (quartiles) | |||
| Q1 | 256 (21.7) | 923 (78.3) | 1179 |
| Q2 | 323 (19.7) | 1314 (80.3) | 1637 |
| Q3 | 371 (19.2) | 1564 (80.8) | 1935 |
| Q4 | 623 (17.5) | 2932 (82.5) | 3555 |
| Extent of resection | |||
| Biopsy-only | 624 (23.6) | 2024 (76.4) | 2648 |
| Subtotal resection | 503 (16.3) | 2592 (83.7) | 2563 |
| Gross total resection | 446 (17.4) | 2117 (82.6) | 3095 |
| Facility cancer program type | |||
| Academic/research | 575 (14.6) | 3364 (85.4) | 3939 |
| Community | 87 (32.7) | 179 (67.3) | 266 |
| Comprehensive community | 624 (24.9) | 1878 (75.1) | 2502 |
| Integrated network | 287 (17.9) | 1312 (82.1) | 1599 |
| Diagnosing hospital | |||
| Elsewhere | 413 (16.4) | 2105 (83.6) | 2518 |
| Reporting facility | 1160 (20.0) | 4628 (80.0) | 5788 |
| Facility location | |||
| New England | 73 (13.2) | 479 (86.8) | 552 |
| East North Central | 249 (18.7) | 1082 (81.3) | 1331 |
| East South Central | 130 (24.4) | 402 (75.6) | 532 |
| Middle Atlantic | 259 (20.3) | 1015 (79.7) | 1274 |
| Mountain | 64 (17.8) | 296 (82.2) | 360 |
| Pacific | 196 (17.2) | 944 (82.8) | 1140 |
| South Atlantic | 346 (19.5) | 1431 (80.5) | 1777 |
| West North Central | 87 (13.7) | 549 (86.3) | 636 |
| West South Central | 169 (24.0) | 535 (76.0) | 704 |
| Urbanicity | |||
| Metro | 1339 (18.9) | 5,732 (81.1) | 7071 |
| Rural | 150 (20.2) | 592 (79.8) | 742 |
| Urban | 84 (17.0) | 409 (83.0) | 493 |
| . | BMM reporting completion . | . | Total . |
|---|---|---|---|
| . | No . | Yes . | . |
| . | n (%) . | n (%) . | . |
| Total | 1573 (18.9) | 6733 (81.1) | 8306 |
| Age at diagnosis, years (yrs) | |||
| 40–44 | 55 (14.8) | 317 (85.2) | 372 |
| 45–49 | 104 (18.4) | 460 (81.6) | 564 |
| 50–54 | 126 (17.5) | 594 (82.5) | 720 |
| 55–59 | 187 (17.0) | 910 (83.0) | 1097 |
| 60–64 | 240 (18.1) | 1086 (81.9) | 1326 |
| 65–69 | 282 (19.8) | 1140 (80.2) | 1422 |
| 70+ | 579 (20.6) | 2226 (79.4) | 2805 |
| Sex | |||
| Male | 911 (18.7) | 3958 (81.3) | 4869 |
| Female | 662 (19.3) | 2775 (80.7) | 3437 |
| Race/Ethnicity | |||
| White, non-Hispanic | 1246 (18.4) | 5529 (81.6) | 6775 |
| Black, non-Hispanic | 94 (20.0) | 375 (80.0) | 469 |
| Hispanic | 128 (23.0) | 429 (77.0) | 557 |
| Asian/Pacific Islander | 45 (19.7) | 183 (80.3) | 228 |
| Other | 60 (21.7) | 217 (78.3) | 277 |
| Prior cancer diagnosis | |||
| No | 1332 (18.8) | 5742 (81.2) | 7074 |
| Yes | 241 (19.6) | 991 (80.4) | 1232 |
| Histopathological type | |||
| Glioblastoma (9440/3) | 1373 (19.8) | 5556 (80.2) | 6929 |
| Astrocytoma (9400/3 or 9401/3) | 173 (17.6) | 810 (82.4) | 983 |
| Oligodendroglioma (9450/3 or 9451/3) | 27 (6.9) | 367 (93.1) | 394 |
| Primary site | |||
| Brain, NOS | 166 (23.4) | 543 (76.6) | 709 |
| Infratentorial | 18 (22.0) | 64 (78.0) | 82 |
| Overlapping lesion | 185 (17.8) | 856 (82.2) | 1041 |
| Supratentorial | 1204 (18.6) | 5270 (81.4) | 6474 |
| WHO grade | |||
| 2 | 57 (10.9) | 466 (89.1) | 523 |
| 3 | 120 (15.5) | 652 (84.5) | 772 |
| 4 | 1396 (19.9) | 5615 (80.1) | 7011 |
| Insurance status | |||
| Private | 608 (18.1) | 2755 (81.9) | 3363 |
| Medicaid | 106 (17.3) | 505 (82.7) | 611 |
| Medicare | 782 (19.9) | 3141 (80.1) | 3923 |
| Other governmental | 24 (13.2) | 158 (86.8) | 182 |
| Uninsured | 53 (23.3) | 174 (76.7) | 227 |
| ZIP code-level household income (quartiles) | |||
| Q1 | 256 (21.7) | 923 (78.3) | 1179 |
| Q2 | 323 (19.7) | 1314 (80.3) | 1637 |
| Q3 | 371 (19.2) | 1564 (80.8) | 1935 |
| Q4 | 623 (17.5) | 2932 (82.5) | 3555 |
| Extent of resection | |||
| Biopsy-only | 624 (23.6) | 2024 (76.4) | 2648 |
| Subtotal resection | 503 (16.3) | 2592 (83.7) | 2563 |
| Gross total resection | 446 (17.4) | 2117 (82.6) | 3095 |
| Facility cancer program type | |||
| Academic/research | 575 (14.6) | 3364 (85.4) | 3939 |
| Community | 87 (32.7) | 179 (67.3) | 266 |
| Comprehensive community | 624 (24.9) | 1878 (75.1) | 2502 |
| Integrated network | 287 (17.9) | 1312 (82.1) | 1599 |
| Diagnosing hospital | |||
| Elsewhere | 413 (16.4) | 2105 (83.6) | 2518 |
| Reporting facility | 1160 (20.0) | 4628 (80.0) | 5788 |
| Facility location | |||
| New England | 73 (13.2) | 479 (86.8) | 552 |
| East North Central | 249 (18.7) | 1082 (81.3) | 1331 |
| East South Central | 130 (24.4) | 402 (75.6) | 532 |
| Middle Atlantic | 259 (20.3) | 1015 (79.7) | 1274 |
| Mountain | 64 (17.8) | 296 (82.2) | 360 |
| Pacific | 196 (17.2) | 944 (82.8) | 1140 |
| South Atlantic | 346 (19.5) | 1431 (80.5) | 1777 |
| West North Central | 87 (13.7) | 549 (86.3) | 636 |
| West South Central | 169 (24.0) | 535 (76.0) | 704 |
| Urbanicity | |||
| Metro | 1339 (18.9) | 5,732 (81.1) | 7071 |
| Rural | 150 (20.2) | 592 (79.8) | 742 |
| Urban | 84 (17.0) | 409 (83.0) | 493 |
Testing/reporting was defined as having a BMM code of 1–9 or 87, while a code of 88 or 99 was defined as no testing and reporting.
Abbreviations: BMM = Brain Molecular Markers.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
